Moody Aldrich Partners LLC bought a new position in IGM Biosciences (NASDAQ:IGMS) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 18,873 shares of the company’s stock, valued at approximately $1,378,000. Moody Aldrich Partners LLC owned approximately 0.06% of IGM Biosciences as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently made changes to their positions in IGMS. Bank of America Corp DE purchased a new stake in IGM Biosciences during the fourth quarter valued at about $29,000. Citigroup Inc. bought a new position in shares of IGM Biosciences during the 4th quarter valued at about $38,000. Exane Derivatives purchased a new position in shares of IGM Biosciences during the 1st quarter valued at about $92,000. SG Americas Securities LLC bought a new stake in IGM Biosciences in the 1st quarter worth approximately $106,000. Finally, Victory Capital Management Inc. bought a new stake in IGM Biosciences in the 4th quarter worth approximately $141,000. Institutional investors own 43.32% of the company’s stock.

Shares of NASDAQ IGMS traded up $0.32 during mid-day trading on Friday, hitting $50.26. The stock had a trading volume of 159,628 shares, compared to its average volume of 73,953. The company has a quick ratio of 28.17, a current ratio of 28.17 and a debt-to-equity ratio of 0.05. IGM Biosciences has a 1 year low of $16.10 and a 1 year high of $80.55. The business has a 50 day moving average price of $65.23 and a two-hundred day moving average price of $54.80.

IGM Biosciences (NASDAQ:IGMS) last issued its earnings results on Thursday, May 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). On average, equities research analysts expect that IGM Biosciences will post -2.7 earnings per share for the current year.

IGMS has been the topic of several research reports. Piper Sandler lifted their price target on shares of IGM Biosciences from $53.00 to $81.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Zacks Investment Research downgraded shares of IGM Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, July 8th. Stifel Nicolaus lifted their price target on shares of IGM Biosciences from $67.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. HC Wainwright initiated coverage on shares of IGM Biosciences in a research note on Wednesday, July 1st. They set a “buy” rating and a $88.00 price target on the stock. Finally, Robert W. Baird initiated coverage on shares of IGM Biosciences in a research note on Thursday, July 16th. They set an “outperform” rating and a $90.00 price target on the stock. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $65.00.

IGM Biosciences Profile

IGM Biosciences, Inc, a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma.

Featured Article: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding IGMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IGM Biosciences (NASDAQ:IGMS).

Institutional Ownership by Quarter for IGM Biosciences (NASDAQ:IGMS)

Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.